Light-Up Probes Based On Fluorogens With Aggregation Induced Emission Characteristics For Cellular Imaging And Drug Screening

Patent metadata

Field	Value
Publication number	US-2016356723-A1
Application number	US-201515114692-A
Country	US
Kind code	A1
Filing date	Jan 27, 2015
Priority date	Jan 27, 2014
Publication date	Dec 8, 2016
Grant date	—

Abstract

The present invention is drawn toward luminogens and chemical compositions comprising a target recognition motif, a hydrophilic moiety, a linking moiety, and at least one luminogen. Additionally presented are methods of: assessing the conversion of a prodrug into its active form, assessing the therapeutic efficacy of a prodrug, detecting glutathione in a biological sample, detecting alkaline phosphatase in a sample, and conducting fluorescence imaging or magnetic resonance imaging with the use of luminogen-containing compositions.

First claim

1 . A chemical composition, comprising: a target recognition motif, a hydrophilic moiety, a linking moiety, and at least one luminogen, wherein the luminogen exhibits aggregation-induced emission properties, and further wherein the target recognition motif, the hydrophilic moiety, the linking moiety, and the at least one luminogen are linked by covalent linkages in a linear array.

2 . The composition of claim 1 , wherein the linking moiety is a prodrug or a cleavable linking group.

3 . The composition of claim 2 , wherein the prodrug is a platinum (IV) complex.

4 .- 5 . (canceled)

6 . The composition of claim 1 , wherein the luminogen is tetraphenylethylene, tetraphenylsilole, or a luminogen having the structure of formula:

or a pharmaceutically acceptable salt thereof, wherein:
R 1 is selected from H, (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C 6 -C 10 )aryl, (C 3 -C 10 )heteroaryl, or (C 2 -C 6 )alkenyl;
each R 2 is independently selected from H, NHR 3 , N(R 3 ) 2 , (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C 6 -C 10 )aryl, (C 3 -C 10 )heteroaryl, —O(C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, CH═CH((C 3 -C 10 )heteroaryl), or CH═CH((C 6 -C 10 )aryl); and
R 3 is selected from H, (C 1 -C 6 )alkyl or (C 3 -C 6 )cycloalkyl;
and wherein the luminogen is optionally and independently substituted with one or more substituents selected from:

(C 3 -C 10 )heteroaryl,

wherein * indicates the point of attachment to the luminogen residue and ** indicates the point of attachment to either the prodrug, the target recognition motif or the hydrophilic peptide.

7 . The composition of claim 1 , wherein the luminogen has the structure of formula:

wherein R 1 is C 2 H 5 or C 6 H 13 ; or wherein the luminogen has the structure of formula:

8 . The composition of claim 1 , wherein the hydrophilic moiety comprises a hydrophilic peptide, a self-assembling peptide, an oligonucleotide, a water soluble polymer, or an alkyl chain functionalized by charged side groups.

9 .- 10 . (canceled)

11 . The composition of claim 8 , wherein the self-assembling peptide is (Ala-Glu-Ala-Glu-Ala-Lys-Ala-Lys) 2 (SEQ ID NO:3).

12 . The composition of claim 1 , wherein the target recognition motif has an affinity for a cell membrane receptor or a cyclic(Arg-Gly-Asp) residue having an affinity for integrin α v β 3 .

13 .- 14 . (canceled)

15 . The composition of claim 2 , wherein the target recognition motif is covalently bonded to the hydrophilic peptide, the hydrophilic peptide is covalently bonded to the prodrug, and the prodrug is covalently bonded to the luminogen.

16 . The composition of claim 2 , wherein the target recognition motif is covalently bonded to the prodrug, the prodrug is covalently bonded to the hydrophilic peptide, and the hydrophilic peptide is covalently bonded to the luminogen.

17 . The composition of claim 2 , wherein the target recognition motif is covalently bonded to the cleavable linking group, the cleavable linking group is covalently bonded to the hydrophilic peptide, and the hydrophilic peptide is covalently bonded to the luminogen.

18 . The composition of claim 1 , having the structure of formula:

or a pharmaceutically acceptable salt thereof.

19 . The composition of claim 15 , having the structure of formula:

or a pharmaceutically acceptable salt thereof.

20 . The composition of claim 16 , having the structure of formula:

or a pharmaceutically acceptable salt thereof.

21 . A method for assessing the conversion of a prodrug into its active form, comprising:
a) incubating a biological sample with the composition of claim 15 under conditions sufficient to form an incubated mixture; and b) analyzing the fluorescence of the incubated mixture of step a) using a microplate reader, wherein an increase in fluorescence intensity as compared to the fluorescence intensity of the composition of claim 15 not in the presence of the biological sample is indicative of the conversion of the prodrug into its active form.

22 . (canceled)

23 . A method for assessing the therapeutic efficacy of a prodrug, comprising:
a) incubating a biological sample comprising live target cells with the composition of claim 16 under conditions sufficient to convert the prodrug into its active form and form an incubated mixture; and b) analyzing the incubated mixture of step a) by fluorescence spectroscopy, wherein an increase in fluorescence intensity as compared to the fluorescence intensity of the composition of claim 16 not in the presence of the biological sample is indicative of the efficacy of the active drug.

24 . A method for detecting glutathione in a biological sample, comprising:
a) incubating a biological sample thought to contain glutathione with the composition of claim 1 under conditions sufficient to form an incubated mixture; and b) analyzing the incubated mixture of step a) by fluorescence spectroscopy, wherein an increase in fluorescence intensity as compared to the fluorescence intensity of the composition of claim 1 not in the presence of the biological sample is indicative presence of glutathione.

25 . (canceled)

26 . A method for the detection of alkaline phosphatase in a sample, comprising:
a) incubating a sample thought to comprise alkaline phosphatase with a compound of the formula:

under conditions sufficient to form an incubated media; and
b) analyzing the incubated media of step a) by fluorescence spectroscopy, wherein an increase in fluorescence intensity of a fluorescence signal at about 641 nm is indicative of the presence of alkaline phosphatase.

27 . (canceled)

28 . A chemical composition, comprising a compound of the formula:

or a pharmaceutically acceptable salt thereof.

29 . A method comprising conducting fluorescence imaging or magnetic resonance imaging wherein said conducting of said fluorescence imaging or said magnetic resonance imaging utilizes the composition of claim 28 .

30 . A luminogen having the structure of formula:

or a pharmaceutically acceptable salt thereof, wherein:
R 1 is selected from H, (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C 6 -C 10 )aryl, (C 3 -C 10 )heteroaryl, or (C 2 -C 6 )alkenyl;
each R 2 is independently selected from H, NHR 3 , N(R 3 ) 2 , (C 1 -C 6 )alkyl,

Assignees

• Nat Univ Singapore
• Univ Hong Kong Science & Tech

Inventors

• Liu Bin
• Shao Jinjun
• Yuan Youyong
• Liang Jing
• Tang Benzhong
• Song Zhegang
• Chen Yilong
• Kwok Tsz Kin

Classifications

• G01N33/5008

  for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics · CPC title

• G01N21/77 Primary

  by observing the effect on a chemical indicator · CPC title

• C07D213/38

  having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom · CPC title

• A61K49/0056

  Peptides, proteins, polyamino acids · CPC title

• C07K1/13

  Labelling of peptides · CPC title